Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report is filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) for the period ending December 29, 2020. The filing documents the results of the Company's 2020 Annual Meeting of Stockholders held on that date.

Key Financial Metrics

This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metric.

Material Changes and Corporate Actions

The filing details the following material corporate actions approved by stockholders:

  • Board Elections: Seven directors were elected to serve until the 2021 annual meeting: Steven Sherman, Jack Peurach, Ted Wang, Ph.D., Charles Li, Ph.D., Stanley Stern, Mary Ann Cloyd, and Rhonda A. Wallen.
  • Equity Plan Amendment: Stockholders approved an increase in the total number of shares authorized for issuance under the Amended and Restated 2014 Equity Incentive Plan from 1,174,286 to 1,974,286 shares.
  • Executive Compensation: The advisory vote on named executive officer compensation was approved.
  • Auditor Ratification: The appointment of OUM & Co., LLP as independent auditors for the year ending December 31, 2020, was ratified.

Voting Results and Management Commentary

Of the 8,316,308 shares outstanding, 5,619,300 shares were present, constituting a quorum. Key voting outcomes include:

  • Director Elections: All seven nominees received majority support. Broker non-votes totaled 3,021,032 for each director.
  • Equity Plan Increase: Approved with 2,109,755 votes for, 463,462 against, and 25,051 abstentions.
  • Executive Compensation: Approved with 2,212,224 votes for, 324,108 against, and 61,936 abstentions.
  • Auditor Ratification: Approved with 5,354,850 votes for, 111,979 against, and 152,471 abstentions.

The filing incorporates by reference a press release dated December 30, 2020, regarding the election of Ms. Cloyd and Ms. Wallen. No specific management commentary on financial outlook or risks is provided in this text.

Investor Verification Checklist

  • Verify the updated share count authorized under the 2014 Equity Incentive Plan (now 1,974,286 shares).
  • Confirm the tenure of the newly elected directors, specifically noting their terms expire at the 2021 annual meeting.
  • Review the full Proxy Statement dated November 12, 2020, for detailed executive compensation data referenced in Proposal 3.
  • Check subsequent filings (e.g., 10-K) for the actual financial performance of the year ending December 31, 2020, as this 8-K contains no financial statements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.